Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Oser MG"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
El Zarif T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Yale School of Medicine, New Haven, Connecticut., Meador CB; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Qiu X; Department of Medicine, Yale School of Medicine, New Haven, Connecticut., Seo JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Davidsohn MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Savignano H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Lakshminarayanan G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., McClure HM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Canniff J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Fortunato B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Li R; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Banwait MK; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Semaan K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.; Eli and Edythe L. Broad Institute, Cambridge, Massachusetts., Eid M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Long H; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts., Hung YP; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts., Mahadevan NR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Oser MG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Piotrowska Z; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.; Eli and Edythe L. Broad Institute, Cambridge, Massachusetts., Hata AN; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.; Eli and Edythe L. Broad Institute, Cambridge, Massachusetts., Berchuck JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Sep 03; Vol. 30 (17), pp. 3798-3811.
Autor:
Duplaquet L; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA., So K; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Biological and Biomedical Sciences Graduate Program, Harvard Medical School, Boston, MA 02115, USA., Ying AW; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Pal Choudhuri S; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Internal Medicine and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA., Li X; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA., Xu GD; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Li Y; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA., Qiu X; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Li R; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Singh S; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA., Wu XS; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, NY 11724, USA., Hamilton S; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Internal Medicine and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA., Chien VD; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Internal Medicine and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA., Liu Q; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Qi J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Somerville TDD; Novartis BioMedical Research, Cambridge, MA 02139, USA., Heiling HM; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Mazzola E; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Lee Y; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Zoller T; Novartis BioMedical Research, Cambridge, MA 02139, USA., Vakoc CR; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, NY 11724, USA., Doench JG; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Forrester WC; Novartis BioMedical Research, Cambridge, MA 02139, USA., Abrams T; Novartis BioMedical Research, Cambridge, MA 02139, USA., Long HW; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Niederst MJ; Novartis BioMedical Research, Cambridge, MA 02139, USA., Drapkin BJ; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Internal Medicine and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA., Kadoch C; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. Electronic address: cigall_kadoch@dfci.harvard.edu., Oser MG; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: matthew_oser@dfci.harvard.edu.
Publikováno v:
Cancer cell [Cancer Cell] 2024 Aug 12; Vol. 42 (8), pp. 1352-1369.e13. Date of Electronic Publication: 2024 Jul 18.
Autor:
Singh S, Gleason CE, Fang M, Laimon YN, Khivansara V, Xie S, Durmaz YT, Sarkar A, Ngo K, Savla V, Li Y, Abu-Remaileh M, Li X, Tuladhar B, Odeh R, Hamkins-Indik F, He D, Membreno MW, Nosrati M, Gushwa NN, Leung SSF, Fraga-Walton B, Hernandez L, Baldomero MP, Lent BM, Spellmeyer D, Luna JF, Hoang D, Gritsenko Y, Chand M, DeMart MK, Metobo S, Bhatt C, Shapiro JA, Yang K, Dupper NJ, Bockus AT, Doench JG, Aggen JB, Liu LF, Levin B, Wang EW, Vendrell I, Fischer R, Kessler B, Gokhale PC, Signoretti S, Spektor A, Kreatsoulas C, Singh R, Earp DJ, Garcia PD, Nijhawan D, Oser MG
Publikováno v:
BioRxiv : the preprint server for biology [bioRxiv] 2024 Aug 01. Date of Electronic Publication: 2024 Aug 01.
Autor:
Singh PNP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Gu W; Division of Regenerative Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA., Madha S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Lynch AW; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Cejas P; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., He R; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Bhattacharya S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Muñoz Gomez M; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Oser MG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Departments of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA 02115, USA., Brown M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Departments of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA 02115, USA., Long HW; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Meyer CA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Zhou Q; Division of Regenerative Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address: jqz4001@med.cornell.edu., Shivdasani RA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Departments of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA. Electronic address: ramesh_shivdasani@dfci.harvard.edu.
Publikováno v:
Cell stem cell [Cell Stem Cell] 2024 Jul 05; Vol. 31 (7), pp. 1038-1057.e11. Date of Electronic Publication: 2024 May 10.
Autor:
Cai L, Gao Y, DeBerardinis RJ, Acquaah-Mensah G, Aidinis V, Beane JE, Biswal S, Chen T, Concepcion-Crisol CP, Grüner BM, Jia D, Jones R, Kurie JM, Lee MG, Lindahl P, Lissanu Y, Lorz Lopez MC, Martinelli R, Mazur PK, Mazzilli SA, Mii S, Moll H, Moorehead R, Morrisey EE, Ng SR, Oser MG, Pandiri AR, Powell CA, Ramadori G, Santos Lafuente M, Snyder E, Sotillo R, Su KY, Taki T, Taparra K, Xia Y, van Veen E, Winslow MM, Xiao G, Rudin CM, Oliver TG, Xie Y, Minna JD
Publikováno v:
BioRxiv : the preprint server for biology [bioRxiv] 2024 May 14. Date of Electronic Publication: 2024 May 14.
Autor:
Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Seo JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Davidsohn MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Fortunato B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Semaan K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Sotudian S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Lakshminarayanan G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Diossy M; Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA., Qiu X; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., El Zarif T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Savignano H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Canniff J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Madueke I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Saliby RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Zhang Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Li R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Jiang Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Taing L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Awad M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Chau CH; Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., DeCaprio JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Figg WD; Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Greten TF; Liver Cancer Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Hata AN; Massachusetts General Hospital Cancer Center, Boston, MA, USA.; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hughes ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ligon KL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Lin N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ng K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Oser MG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Meador C; Massachusetts General Hospital Cancer Center, Boston, MA, USA.; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Parsons HA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Pomerantz MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Rajan A; Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA., Ritz J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Thakuria M; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Long H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Berchuck JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Szallasi Z; Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA.; Danish Cancer Institute, Copenhagen, Denmark.; Department of Bioinformatics and Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. matthew_freedman@dfci.harvard.edu.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. matthew_freedman@dfci.harvard.edu.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA. matthew_freedman@dfci.harvard.edu.
Publikováno v:
Nature medicine [Nat Med] 2024 Mar; Vol. 30 (3), pp. 907.
Autor:
Oser MG; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA. matthew_oser@dfci.harvard.edu.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. matthew_oser@dfci.harvard.edu., MacPherson D; Division of Human Biology, Fred Hutch Cancer Center, Seattle, WA, 98109, USA., Oliver TG; Department of Pharmacology & Cancer Biology, Duke University, Durham, NC, 27708, USA., Sage J; Department of Pediatrics, Stanford University, Stanford, CA, 94305, USA.; Department of Genetics, Stanford University, Stanford, CA, 94305, USA., Park KS; Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA, 22903, USA. kp5an@virginia.edu.
Publikováno v:
Oncogene [Oncogene] 2024 Feb; Vol. 43 (7), pp. 457-469. Date of Electronic Publication: 2024 Jan 08.
Autor:
Li Y; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA., Mahadevan NR; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA., Duplaquet L; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA., Hong D; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA., Durmaz YT; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA., Jones KL; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, MA 02210, USA., Cho H; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA., Morrow M; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, MA 02210, USA., Protti A; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, MA 02210, USA., Poitras MJ; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, MA 02210, USA., Springer BF; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, MA 02210, USA., Bronson RT; Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02215, USA., Gong X; Loxo@Lilly, Indianapolis, IN 46225, USA., Hui YH; Loxo@Lilly, Indianapolis, IN 46225, USA., Du J; Loxo@Lilly, Indianapolis, IN 46225, USA., Southard J; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Translational Immunogenomics Lab, Dana Farber Cancer Institute, Boston, MA, USA., Thai T; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA., Li S; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Translational Immunogenomics Lab, Dana Farber Cancer Institute, Boston, MA, USA., Lizotte PH; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Gokhale PC; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, MA 02210, USA., Nguyen QD; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, MA 02210, USA., Oser MG; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: matthew_oser@dfci.harvard.edu.
Publikováno v:
Cell reports. Medicine [Cell Rep Med] 2023 Nov 21; Vol. 4 (11), pp. 101282.
Autor:
Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Seo JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Davidsohn MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Fortunato B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Semaan K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Sotudian S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Lakshminarayanan G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Diossy M; Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA., Qiu X; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., El Zarif T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Savignano H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Canniff J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Madueke I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Saliby RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Zhang Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Li R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Jiang Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Taing L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Awad M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Chau CH; Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., DeCaprio JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Figg WD; Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Greten TF; Liver Cancer Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Hata AN; Massachusetts General Hospital Cancer Center, Boston, MA, USA.; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hughes ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ligon KL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Lin N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ng K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Oser MG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Meador C; Massachusetts General Hospital Cancer Center, Boston, MA, USA.; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Parsons HA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Pomerantz MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Rajan A; Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA., Ritz J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Thakuria M; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Long H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Berchuck JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Szallasi Z; Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA.; Danish Cancer Institute, Copenhagen, Denmark.; Department of Bioinformatics and Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. matthew_freedman@dfci.harvard.edu.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. matthew_freedman@dfci.harvard.edu.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA. matthew_freedman@dfci.harvard.edu.
Publikováno v:
Nature medicine [Nat Med] 2023 Nov; Vol. 29 (11), pp. 2737-2741. Date of Electronic Publication: 2023 Oct 21.